loader2
Partner With Us NRI

CAPLIN POINT LABORATORIES SHARE PRICE TODAY

Company details

1,505.50
1,558.10
842.30
1,619.05
6M Return 5.59%
1Y Return 78.04%
Mkt Cap.(Cr) 11,609.77
Volume 57,517
Div Yield 0.16%
OI
-
OI Chg %
-
Volume 57,517
NSE

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23.
  • Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23.
  • Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23.
  • Gross Margin%: 56.3%, increased from 55.9% in Q3FY23.
  • EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23.
  • EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23.
  • PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23.
  • PBT Margin%: 32.1%, increased from 28.9% in Q3FY23.
  • PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23.
  • PAT Margin%: 26.5%, increased from 25.2% in Q3FY23.

Consolidated 9MFY24:

  • Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23.
  • Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23.
  • Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23.
  • Gross Margin%: 57.1%, increased from 54.8% in 9MFY23.
  • EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23.
  • EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23.
  • PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23.
  • PBT Margin%: 32.4%, increased from 29.2% in 9MFY23.
  • PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23.
  • PAT Margin%: 26.4%, increased from 24.6% in 9MFY23.

Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows".

 

Result PDF

View Other Company Results

Caplin Point Laboratories Shares SWOT Analysis

Strengths (10)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Low Debt

Weakness (4)

  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Low Piotroski Score : Companies with weak financials

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Promoter decreasing their shareholding
Discover More

Resistance and support

R1 1,555.2
R2 1,582.9
R3 1,607.8
Pivot

1,530.33

S1 1,502.6
S2 1,477.7
S3 1,450.0
EMA SMA
1,485.6
1,434.2
1,390.4
1,301.7
1,489.2
1,409.2
1,368.8
1,334.0
Delivery and volume
Discover More
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2021-09-09 908.19 381306 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2021-09-09 908.54 381306 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2021-07-27 957.62 414981 NSE
Discover More
Name Category Shares
P VIJAYALAKSHMI PROMOTER 24.71%
PAARTHIPAN C C PROMOTER 18.64%
ASHOK GORKEY PARTHEEBAN PROMOTER 11.91%
PARTHEEBAN VIVEK SIDDARTH PROMOTER 11.84%
MAY INDIA PROPERTY PRIVATE LIMITED PROMOTER 2.79%

OUR RESEARCH VIEW

Investment recommendation
Well-poised to maintain growth with focused capex…
Call Date
19 Mar 2024
Entry Price 1,275.00
Target Price 1,535.00
Duration
12-18 Month
BUY View Report
DISCOVER MORE

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Caplin Point Laboratories Stocks Comparison

Financials( ₹ in Cr) Caplin Point Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,527.40 1,714.25 1,575.00 4,790.60 1,206.05
% Change 1.45 2.91 5 5.36 0.02
Mcap ₹ Cr 11,609.77 411,306.00 127,184.09 127,175.58 121,356.85
Revenue TTM ₹ Cr 1,466.73 48,496.85 15,790.60 7,845.00 19,547.40
Net Profit TTM ₹ Cr 376.99 9,648.44 2,513.47 1,600.00 3,854.40
PE TTM 25.39 41.15 28.67 79.37 31.45
1 Year Return 78.04 56.55 49.32 28.80 93.98
ROCE 26.56 17.20 14.76 16.41 23.94
ROE 25.72 16.13 10.66 12.15 20.64
DISCOVER MORE
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,880.48 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 3,555.27 41,445.87
LAST 3M 81,242.17 56,953.52
LAST 6M 176,360.83 56,552.99
LAST 12M 304,497.96 86,223.40

Caplin Point Laboratories Information

Stock PE (TTM)
25.39
Promoter Holding
70.56%
Book Value
304.6577
ROCE
26.56%
ROE
25.72%
Description

  • Caplin Point Laboratories Ltd. is a fast-growing, fully integrated pharmaceutical company thriving in Francophone Africa and Latin America. It manufactures a wide range of creams, ointments, and other external application preparations, along with regular segments of pharmaceutical formulations. The company was incorporated in 1990, with its headquarters in Chennai. Its total income for the June 2022 quarter was Rs 360.27 crore, up 2.71% from Rs 350.75 crore in the March 2022 quarter. On 30 August 2022, the company’s market capitalisation stood at Rs 5,903 crore.  

    The company’s Bombay Stock Exchange listing code is 524742, and the National Stock Exchange listing code is CAPLIPOINT.  

    Caplin Point Laboratories Ltd. is one of the leading suppliers of pharmaceuticals in the markets of Latin America, Southern and Francophone Africa, and the Caribbean, with more than 4,000 product licenses worldwide. The company prospers on a unique business model of owning distribution networks, predominantly targeting the bottom of the pyramid.  

    On 30 June 2022, the company’s shareholding pattern reflected a 1.11% domestic institutional investor stake, a 2.03% foreign institutional investor stake, a 27.97% public stake, and a 68.88% promoter stake. In the June 2022 quarter, promoter holdings decreased from 68.89% to 68.88%, mutual fund holdings decreased from 1.19% to 1.06%, and FII holdings decreased from 2.07% to 2.03%.  

    The company’s board of directors comprises Mr C CPaarthipan, Dr Sridhar Ganesan, Mr D Sathyanarayanan, Mr V Thirumalai, Dr KC John, Dr (Mrs) C K Gariyali, and Mr R Viswanathan. The auditors of the company are CNGSN & Associates LLP. On 30 June 2022, the company had a total of 7.58 crore shares outstanding.  

    On 30 August 2022, Caplin Point Laboratories Ltd.’s share price closed at Rs 776.90 on BSE and at Rs 778.80 on NSE. The 52-week high for Caplin Point Laboratories Ltd.’s share price was Rs 1,008.40, and the 52-week low for the company’s share price was Rs 626.  

    As of July 2022, the company’s top mutual fund holdings included Taurus Discovery (Midcap) Fund, Taurus Ethical Fund, and Quant Small Cap Fund, with a 3.36% stake, 3.08% stake, and 2.43% stake, respectively.  

    Caplin Point Laboratories Ltd.’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

Read More
Registered Address

Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat, Chennai, Tamil Nadu, 600096

Tel : 91-44-24968000/71148000/28156653
Email : investor:caplinpoint.net; info:caplinpoint.net
Website : http://www.caplinpoint.net
Registrar

Knack Corporate Services Pvt L

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 524742
NSE Code : CAPLIPOINT
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE475E01026

CAPLIN POINT LABORATORIES SHARES FAQs

You can buy Caplin Point Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Caplin Point Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 26, 2024 03:53 PM the closing price of Caplin Point Laboratories Ltd was Rs.1,527.40.

The latest PE ratio of Caplin Point Laboratories Ltd as of Jul 26, 2024 03:53 PM is 25.39

The latest PB ratio of Caplin Point Laboratories Ltd as of Jul 26, 2024 03:53 PM is 0.20

The 52-week high of Caplin Point Laboratories Ltd share price is Rs. 1,619.05 while the 52-week low is Rs. 842.30

According to analyst recommendations, Caplin Point Laboratories Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a companys shares with the total number of shares outstanding. As of Jul 26, 2024 03:53 PM, the market cap of Caplin Point Laboratories Ltd stood at Rs. 11,609.77 Cr.

Disclaimer
Download App

Download Our App

Play Store App Store
market app